Genetic testing is fast becoming vital for patient diagnosis, not just in rare disease research, but also for marketed drug access.
As genetic testing can be quite expensive, rare disease drug companies have been “assisting patients” by sponsoring testing. But how they go about sponsored testing is very important, as Ultragenyx and Biomarin have recently discovered.
https://www.justice.gov/opa/pr/phar...y-6-million-allegedly-paying-kickbacks-induce
https://www.natlawreview.com/articl...ls-continued-investigations-sponsored-testing
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |